Search

A new report discusses research findings on obesity from the Sheng Yushou Center of Cell Biology and Immunology. The study aimed to investigate the role of glucocorticoid and mineralocorticoid receptors in the regulation of energy homeostasis. The researchers used mouse models to study the deletion of these receptors in corticotropin-releasing hormone (CRH) neurons and found that their deletion resulted in obesity and insulin resistance. The study suggests that targeting both receptors simultaneously could be a potential approach to counteract obesity. [Extracted from the article]

A recent study conducted by researchers at West Texas A&M University examined the effects of stress on beef steers. The study found that the administration of corticotropin-releasing hormone (CRH) and vasopressin (VP) affected the complete blood count and serum chemistry of the steers. Additionally, the duration of treatment exposure influenced the physiological responses to the stress challenge. These findings highlight the impact of stress on metabolic, hematologic, and rumen fermentation parameters in growing beef steers. For more information, readers can refer to the journal article published in Translational Animal Science. [Extracted from the article]

A patent application titled "Growth Hormone-Releasing Hormone Peptides And Formulations Thereof" has been published online by the US Patent and Trademark Office. The inventors, Russell Glenn and Justin Hai, have developed compositions containing sermorelin, a growth hormone-releasing hormone (GHRH) peptide, for oral administration with high bioavailability and absorption rates. The compositions may also include glycine, a delivery-enhancing agent, a stimulatory agent, a steroid, a vitamin, or an excipient. The patent application provides detailed claims and methods for preparing tablets and improving the health of subjects. [Extracted from the article]

A recent report from the Russian Academy of Sciences discusses the effects of gonadotropin-releasing hormone (GnRH) on the immune organs, such as the red bone marrow, thymus, spleen, and lymph nodes. The use of GnRH drugs leads to changes in these organs, including the replacement of red bone marrow with yellow marrow and an increase in lymphoid and myeloid progenitor cells. However, there is still limited understanding of the physiological mechanisms of immunomodulation in these conditions. Further research is needed to develop effective systems for immune control. [Extracted from the article]

According to a preprint abstract, researchers have found that manipulating the expression of corticotropin-releasing hormone (Crh) in the paraventricular nucleus of the hypothalamus (PVH) does not affect anxiety-like behaviors in mice with primary adrenal insufficiency or those treated with dexamethasone (DEX). The study compared mice with different genotypes and treatments using behavioral tests and measured Crh expression and hormone levels. The findings suggest that low Crh expression is associated with reduced anxiety, but extreme deficiency may be required, and glucocorticoids may not modulate anxiety behaviors through Crh expression. However, this research has not yet undergone peer review. [Extracted from the article]

A recent study conducted at Sasebo City General Hospital in Japan focused on cotyledonoid-dissecting leiomyoma, a rare form of uterine leiomyoma that is often misdiagnosed as a malignant tumor. The researchers presented a case study of a 45-year-old woman who underwent a laparoscopic biopsy of a large pelvic mass, which was later diagnosed as a cotyledonoid-dissecting leiomyoma based on pathological and image findings. The study highlighted the utility of laparoscopic biopsy due to its minimal invasiveness and diagnostic accuracy. Additionally, the researchers suggested that the preoperative use of Gonadotropin-releasing hormone (GnRH) analogs may be beneficial in reducing surgical stress when treating cotyledonoid-dissecting leiomyomas. [Extracted from the article]

A recent study conducted by researchers at the University of Tokyo in Japan has found that the opioid receptor agonist nalfurafine can inhibit the activity of the gonadotropin-releasing hormone (GnRH) pulse generator in female goats, leading to a suppression of pulsatile luteinizing hormone (LH) secretion. Nalfurafine is currently used as an anti-pruritic drug and could potentially be used as a reproductive inhibitor in mammals. The study was supported by the Japan Society for the Promotion of Science and has been peer-reviewed. Further research is needed to explore the potential applications of nalfurafine in reproductive medicine. [Extracted from the article]

A recent study conducted at the University of Debrecen in Hungary explored the expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in pediatric patients with hematological and oncological disorders. The researchers found that GHRH and its receptor were expressed in a significant number of the samples studied, suggesting that they could potentially serve as molecular targets for diagnosis and therapy. The study highlights the importance of further investigation into GHRH and its receptor in childhood diseases. This information may be valuable for researchers and medical professionals working in the field of pediatric oncology. [Extracted from the article]

The article reports on a study evaluating the efficacy of long-acting gonadotropin-releasing hormone analogues for managing central precocious puberty. Topics discussed include the comparative effectiveness of subcutaneous leuprolide acetate versus intramuscular leuprolide acetate, hormone suppression levels, and the potential for similar use in clinical practice.

A recent study conducted at King Edward Medical University in Lahore, Pakistan compared the effects of two different treatments on the volume reduction of uterine leiomyomas (fibroids) in premenopausal women. The study compared the use of a gonadotropin-releasing hormone agonist (leuprolide acetate) with an aromatase inhibitor (letrozole). The results showed that both treatments led to a reduction in fibroid volume, but there was no statistically significant difference between the two treatments. This research provides valuable information for medical professionals considering non-surgical treatments for uterine leiomyomas. [Extracted from the article]

A recent study conducted in Patras, Greece, explored the use of gonadotropin-releasing hormone agonists (GnRH-a) in improving pregnancy rates in women with endometriosis undergoing assisted reproduction techniques. The researchers conducted a literature review and found that while the regimen may have a positive clinical effect on severe cases of endometriosis, it is not routinely recommended to improve pregnancy rates. The study highlights the close relationship between endometriosis and infertility and the need for further research in this area. This information is relevant for obstetricians, gynecologists, and family physicians. [Extracted from the article]

A new report from the University of Chicago presents findings on the use of 5-alpha reductase inhibitors (5-ARIs) as an alternative to LHRH-agonists in the treatment of prostate cancer. The study found that men treated with 5-ARIs had better preservation of hormonal quality of life without negative effects on biochemical outcomes after 5 years of follow-up. This approach may be particularly beneficial for men at high risk of toxicities. The research suggests that using 5-ARIs in combination with radiation therapy can lead to improved preservation of quality of life and comparable disease outcomes to standard treatment. [Extracted from the article]

A new report discusses research findings on pituitary hormone-releasing hormones, specifically focusing on a rare disorder of sex development called true hermaphroditism. The disorder is characterized by the simultaneous presence of testicular and ovarian tissue in the same individual. The study examines a case of a patient with 46 XX true hermaphroditism who also had Kallmann syndrome, a developmental disease associated with gonadotropin-releasing hormone deficiency and anosmia. The research highlights the rarity of this syndrome and the unique genetic mutations found in the patient. For more information, readers can refer to the journal article provided. [Extracted from the article]

A recent study conducted by researchers at Tri-Service General Hospital in Taiwan compared the effectiveness of high-intensity focused ultrasound (HIFU) combined with either gonadotropin-releasing hormone agonist (GnRH-a) or levonorgestrel-releasing intrauterine system (LNG-IUS) for the treatment of adenomyosis. The study found that the combination therapy of HIFU and LNG-IUS was more effective in treating dysmenorrhea (pain during menstruation) and menorrhagia (excessive menstrual bleeding) compared to HIFU and GnRH-a. However, the researchers caution that the conclusion should be interpreted with caution due to significant heterogeneity. Further research is needed in this area. [Extracted from the article]

A recent study conducted at Sun Yat-sen University in Guangzhou, China, explored the effectiveness and safety of different dosage forms of gonadotropin-releasing hormone (GnRH) agonist in premenopausal hormone receptor-positive breast cancer patients. The study included 1109 patients who were treated with GnRH agonist plus selective estrogen receptor modulator or aromatase inhibitor. The results showed that both the 1-month and 3-month GnRH agonist regimens achieved more than 90% estradiol (E2) inhibition within 24 months, confirming the noninferiority of the 3-month regimen. The study concluded that the ovarian function suppression with the 3-month GnRH agonist was not inferior to that with the 1-month regimen, regardless of age or combination with other medications. [Extracted from the article]

A recent report from the University of Alabama Birmingham discusses the effects of growth hormone-releasing hormone deficiency on lifespan and metabolic resilience during high-fat feeding in mid and late life. The study found that mice with growth hormone-releasing hormone deficiency had lower body weight, higher body fat accumulation, improved insulin sensitivity, and an extended lifespan. These findings challenge the idea that adipose tissue accumulation is solely responsible for the negative health effects of obesity. The research suggests that growth hormone signaling may play a role in the development of adverse effects associated with obesity. [Extracted from the article]

A recent study conducted at the University of Alabama Birmingham explored the effects of growth hormone deficiency on aging and longevity. The researchers analyzed serum samples and liver tissue from growth hormone-releasing hormone knockout mice, a model for enhanced longevity. They found that older mice exhibited significant reductions in ceramide levels, which are associated with aging-related tissue defects. The study provides evidence of disrupted ceramide metabolism in long-lived mammals and sheds light on the connection between growth hormone deficiency, ceramide levels, and lifespan extension. The research was supported by the National Institutes of Health. [Extracted from the article]

A recent study from the University of Sao Paulo explores the use of personalized medicine in fertility preservation for patients undergoing cancer treatment. The study discusses various techniques, such as cryopreservation of oocytes and embryos, as well as the use of gonadotropin-releasing hormone (GnRH) agonists. The review highlights the challenges and controversies associated with these approaches, emphasizing the need for personalized treatment protocols and collaboration among healthcare professionals. The research calls for further refinement of these techniques to improve reproductive outcomes for patients facing fertility-impairing treatment. [Extracted from the article]

This document provides information about a clinical trial study that aims to evaluate the effectiveness of darolutamide in addition to androgen deprivation therapy (ADT) for patients with prostate adenocarcinoma. The study will enroll 108 male patients aged 18-80 years who have undergone radical prostatectomy and pelvic lymph node dissection. The primary completion date for data collection is July 1, 2026. The study is being conducted in China and is sponsored by Peking University Third Hospital in collaboration with Bayer. [Extracted from the article]

A recent study conducted by the Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz in Mexico has found that circadian synchronization of feeding can reduce anxiety levels in rats subjected to food restriction. The researchers compared the corticosterone blood concentration and anxiety parameters of rats fed ad libitum or calorie-restricted diets with all-day or intermittent fasting food access. They found that circadian feeding synchronization reduced body weight, food intake, and anxiety levels in both groups with ad libitum or restricted food access. The study suggests that synchronizing feeding with the activity phase may help improve diet therapy adherence in patients. [Extracted from the article]

A report from the University of Porto in Portugal discusses the role of corticotropin-releasing hormone (CRH) in the development of obesity. The researchers highlight the importance of biological conditions during fetal life in programming energy homeostasis systems and influencing the risk of obesity and metabolic diseases. The review aims to summarize the effects of CRH peptides on obesity from fetal life to adulthood. This research has been peer-reviewed and provides valuable insights into the pathophysiology of obesity. [Extracted from the article]

This article discusses the effects of thyrotropin-releasing hormone (TRH) on food intake in mammals. The research, conducted at the National Autonomous University of Mexico (UNAM), explores the various pharmacological effects of TRH and its impact on appetite. The study reveals that peripheral injection of TRH generally leads to a temporary decrease in food intake, while central administration of TRH can have either anorexic or orexigenic effects depending on the site of injection. The researchers suggest that further investigation into the specific neurons involved in TRH's role in food intake control is necessary. [Extracted from the article]

A recent study conducted by researchers at Marshall University examined the effects of puberty blocking treatment on reproductive function in young female rats. The study found that the treatment led to a reduction in the mass of uteri and ovaries, as well as a disruption in follicle development and corpora lutea health. However, after four weeks of drug withdrawal, the reproductive organ mass and morphology recovered. The study suggests that these physiological effects should be considered when administering puberty blocking treatment. No external funding was used to support this research. [Extracted from the article]

Kissei Pharmaceutical Co. Ltd. has been issued a patent for dosing regimens of a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis. Endometriosis is a gynecological condition characterized by the presence of endometrial-like tissue outside the uterus, which can cause infertility and various pain symptoms. The patent describes methods of dosing a patient with a GnRH antagonist based on the level of certain hormones in the patient's body, such as anti-Mullerian hormone (AMH) or b17-estradiol (E2). The invention aims to reduce endometriosis-associated pain without inducing hypo-estrogenic side effects. The patent also includes information on the compound represented by formula (II) and its administration. [Extracted from the article]

A study conducted by researchers at the University of Missouri explores the effects of chronic intermittent hypoxia (CIH) on the activity of the nucleus tractus solitarii (nTS) in the brainstem. The nTS plays a crucial role in regulating cardiorespiratory homeostasis and adapting to stressors. The researchers hypothesized that oxytocin (OT) and corticotropin-releasing hormone (CRH) would increase nTS activity following CIH. The study found that CIH exaggerated nTS activity, excitatory synaptic currents, and calcium influx in response to CRH, which were further enhanced by the addition of OT. These findings demonstrate the impact of intermittent hypoxia on neuropeptides and their function in nTS activity. [Extracted from the article]

A new report from Johns Hopkins University School of Medicine discusses a rare case of Cushing's syndrome caused by a silent pheochromocytoma that secretes both adrenocorticotropic hormone (ACTH) and corticotropin-releasing hormone (CRH). The patient experienced symptoms such as fatigue, muscle weakness, weight gain, and hypertension. Imaging studies revealed an adrenal mass, and after treatment with metyrapone and alpha blockade, the patient underwent adrenalectomy. Pathology confirmed the presence of a pheochromocytoma that stained for ACTH and CRH. The study highlights the importance of considering pheochromocytoma in patients with ACTH-dependent hypercortisolism, even in the absence of excessive catecholamine secretion. [Extracted from the article]

A recent study conducted by researchers at the University of Leuven in Belgium explored the effects of corticotropin-releasing hormone (CRH) on gastric electrical activity and sensorimotor function in healthy volunteers. The study found that peripheral CRH infusion accelerated gastric-emptying rate and increased postprandial gastric response, accompanied by a rise in symptoms. However, CRH did not alter gastric sensitivity or meal-induced accommodation. These findings suggest a significant link between stress and dyspeptic symptoms, with CRH playing a pivotal role in mediating these effects. [Extracted from the article]

This document provides information about a Phase 2 clinical trial for the drug Debio 4228, which is being studied as a treatment for prostate cancer. The trial aims to evaluate the safety and effectiveness of different doses of Debio 4228 administered through intramuscular injection. The trial is not yet recruiting participants and is expected to be completed in April 2026. The eligibility criteria for participants include having locally advanced/metastatic prostate cancer and being a candidate for continuous androgen deprivation therapy. The trial is being conducted by Debiopharm International SA. [Extracted from the article]

A recent study conducted at Korea University Ansan Hospital compared the effectiveness of the triptorelin stimulation test with the classic gonadotropin-releasing hormone (GnRH) stimulation test in diagnosing central precocious puberty (CPP) in girls. The study included 100 girls with premature thelarche who underwent evaluation. The results showed that the triptorelin test had similar trends of luteinizing hormone (LH) elevation and diagnostic rate compared to the traditional GnRH test, suggesting that it may be a valid alternative for differentiating CPP from self-limiting premature thelarche. The study also found that a triptorelin stimulation test for up to 120 minutes was sufficient to diagnose CPP. [Extracted from the article]

A recent study conducted by researchers at the University of Buenos Aires in Argentina has found that the drug valproate can decrease blood pressure in rats by affecting the DNA methylation and gene expression of the thyrotropin-releasing hormone (TRH) promoter. The study showed that valproate reduced TRH mRNA expression and increased DNA methylation in the SHR rat model of hypertension. Interestingly, these effects were also observed in the offspring of rats treated with valproate, suggesting a transgenerational inheritance of the blood pressure-lowering effects. This research provides insights into the role of epigenetic mechanisms in blood pressure regulation and inheritance. [Extracted from the article]

Researchers from the University of Toronto have conducted a study on the involvement of microRNAs in the dysregulation of gonadotropin-releasing hormone (GnRH) gene expression caused by palmitate, a saturated fatty acid. The study found that palmitate downregulated six specific microRNAs (miR-125a, miR-181b, miR-340, miR-351, miR-466c, and miR-503) in hypothalamic neurons, and this repression was attenuated by co-treatment with oleate. The researchers concluded that palmitate indirectly regulates GnRH at both the pre- and post-transcriptional levels by altering the expression levels of miR-466c and miR-340, which in turn regulate transcription factor expression levels. This study provides insights into the mechanisms underlying the dysregulation of GnRH and reproductive function caused by diets high in saturated fatty acids. [Extracted from the article]

A new report from the Department of Obstetrics and Gynecology in Jerusalem, Israel, presents fresh data on Pituitary Hormone-Releasing Hormones. The research aimed to evaluate the effect of the time interval between gonadotropin-releasing hormone (GnRH) agonist trigger administration and oocyte retrieval in GnRH antagonist cycles for non-medical oocyte cryopreservation. The study found that the time interval did not significantly affect oocyte yield and maturation rate. The research was supported by the Hebrew University of Jerusalem and has been peer-reviewed. [Extracted from the article]

A clinical trial, NCT06369610, is currently underway to test the effectiveness of risk-based de-escalated hormone therapy with radiation in treating patients with prostate cancer. The trial aims to determine if combining androgen deprivation therapy (ADT) with radiation therapy can effectively treat high-risk prostate cancer. The trial will assess various factors such as recovery of hormonal levels, toxicity, quality of life, impotence, and survival rates. The trial is currently in Phase II and is expected to be completed by April 2027. Additionally, there is information about alternative names for medical procedures and imaging techniques, as well as details about another clinical trial for the treatment of high-risk prostate adenocarcinoma. This trial aims to evaluate different treatment approaches, including ADT, radiation therapy, and the use of abiraterone acetate. The trial is not yet recruiting participants and is expected to be completed by April 2027. The eligibility criteria for participants are outlined, and the study is being conducted in the United States by the Mayo Clinic. [Extracted from the article]

A recent report from Southwest Medical University discusses the impact of adjuvant gonadotropin-releasing hormone agonist (GnRH-a) on pregnancy outcomes in women with endometriosis following conservative surgery. The study analyzed 17 studies involving 2,485 patients and found that the use of GnRH-a after surgery resulted in a slightly higher pregnancy rate and a shorter time to conceive. However, there were no significant differences in other evaluated outcomes. The researchers suggest that incorporating adjuvant GnRH-a after conservative surgery may be beneficial for women with endometriosis, particularly before Assisted Reproductive Technology (ART), but further research is needed to confirm these potential advantages. [Extracted from the article]

A study conducted at Taipei Medical University in Taiwan compared the effects of gonadotropin-releasing hormone (GnRH) antagonist and agonist treatments on cardiovascular disease (CVD) risk in patients with prostate cancer (PCa) and pre-existing CVD. The study found that patients treated with GnRH antagonists had lower risks of composite cardiovascular events and major adverse cardiovascular events (MACE) compared to those treated with GnRH agonists. This association was observed in patients with metastasis at diagnosis and those receiving androgen deprivation therapy (ADT) for more than six months. The study suggests that GnRH antagonist use may be beneficial for reducing CVD risk in PCa patients with pre-existing CVD. [Extracted from the article]

A recent study published in Renal Replacement Therapy discusses the case of a 53-year-old man on hemodialysis who developed hypothyroidism after being treated with roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor. The patient had also received multiple blood transfusions and was diagnosed with iron overload. The study suggests that regular monitoring of thyroid function may be necessary in patients with renal anemia who are treated with roxadustat, especially those at high risk of thyroid dysfunction. This case highlights the potential for roxadustat to impair thyroid-stimulating hormone secretion. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Anhui Medical University in China has investigated the neural mechanisms underlying the anxiolytic effects of dexmedetomidine, a medication used to treat anxiety. The researchers found that dexmedetomidine reduced anxiety-like behaviors in mice and inhibited the excitability of corticotropin-releasing hormone-producing hypothalamic paraventricular neurons. Activation of these neurons increased anxiety-like behaviors, while inhibition had the opposite effect. The study suggests that the anxiolytic effects of dexmedetomidine are mediated through the inhibition of these specific neurons in the hypothalamus. [Extracted from the article]

A recent study conducted at Tel Aviv University aimed to determine if the follicular GnRH agonist challenge test (FACT) could predict suboptimal response to GnRH agonist trigger in non-medical oocyte cryopreservation cycles. The study included 91 women undergoing non-medical fertility preservation. The results showed that suboptimal response to agonist trigger, as assessed by post-trigger LH levels, was rare. The researchers concluded that FACT could be used as a tool to predict adequate LH levels elevation after agonist ovulation trigger, particularly in high responders. Further studies should focus on optimizing agonist trigger efficacy assessment and prediction. [Extracted from the article]

A recent study conducted by researchers at the University of California San Diego (UCSD) examined the cardiovascular risks associated with different types of hormone therapies for prostate cancer. The study analyzed real-world clinical practice data from over 45,000 men with prostate cancer who received androgen deprivation therapy (ADT). The findings showed that the risk of major adverse cardiovascular events (MACE) and all-cause mortality was higher for patients treated with a gonadotropin-releasing hormone (GnRH) antagonist compared to those treated with a luteinizing hormone-releasing hormone (LHRH) agonist. The study also identified several demographic and risk factors that influenced MACE risk, including age, metastasis, personal MACE history, and race. This research provides valuable insights into the cardiovascular risks associated with different hormone therapies for prostate cancer. [Extracted from the article]

A recent report discusses research conducted at Northeastern University on the relationship between early life adversity and anxiety disorders in females. The study focused on the impact of childhood maltreatment and maternal separation on the timing of puberty in female rats. The researchers found that these forms of adversity led to earlier puberty in females, as well as increased expression of genes involved in pubertal regulation. Additionally, the study found a correlation between early puberty and higher levels of anxiety-like behavior. These findings suggest a potential link between accelerated puberty and anxiety in females. The research was supported by the National Institutes of Health. [Extracted from the article]

A recent study conducted by researchers at the University of Michigan explores the potential link between polycystic ovary syndrome (PCOS) and disruptions in gonadotropin-releasing hormone (GnRH) secretion patterns. The study focused on female mice that were prenatally androgenized (PNA) to mimic the neuroendocrine abnormalities observed in PCOS patients. The researchers found that PNA treatment and development altered the potassium currents in GnRH neurons, potentially contributing to differential neuron function before and after puberty, as well as in disease states such as PCOS. This research provides valuable insights into the underlying mechanisms of PCOS and may have implications for future treatments. [Extracted from the article]

A recent study conducted by researchers at Shandong University in China investigated the impact of hormone replacement therapy (HRT) on pregnancy outcomes in patients with a history of endometrial polyps (EPs) undergoing frozen-thawed embryo transfer (FET). The study included 395 women who underwent their first single euploid FET cycle and were divided into three groups based on endometrial preparation protocols. The results showed that there were no significant differences in live birth rates, miscarriage rates, ectopic pregnancy rates, premature live birth rates, or pregnancy complications among the three groups. The researchers concluded that gonadotropin-releasing hormone agonist combined with HRT did not improve pregnancy outcomes in patients with a history of EPs. [Extracted from the article]

A recent study conducted by researchers at the University of Leuven (KU Leuven) in Belgium explored the effects of corticotropin-releasing hormone (CRH) on gastric electrical activity and sensorimotor function in healthy volunteers. The study aimed to investigate the impact of peripheral CRH infusion on meal-related gastrointestinal symptoms, gastric motility, and sensitivity. The results showed that CRH exposure led to a decrease in gastric emptying half time and an increase in gastric amplitude, saliva cortisol levels, and postprandial symptom severity. However, there were no significant differences in discomfort thresholds, gastric compliance, and accommodation between CRH and placebo. This research contributes to our understanding of the role of CRH in gut-brain interactions and stress-related gastrointestinal disorders. [Extracted from the article]

A recent study conducted at the University of North Carolina Chapel Hill examined the impact and role of hypothalamic corticotropin-releasing hormone (CRH) neurons in withdrawal from chronic alcohol consumption in female and male mice. The researchers found that alcohol consumption blunted the stress response in female mice during acute withdrawal, and withdrawal engendered a hyperexcitable phenotype of CRH neurons in females. Chemogenetic inhibition of these neurons reduced stress response in female mice with a history of alcohol drinking. The study suggests that stress-responsive CRH neurons in females may be particularly affected by alcohol consumption, potentially contributing to increased heavy alcohol use as a coping mechanism for stress. [Extracted from the article]

A recent study conducted at the University of Genoa in Italy has provided new insights into gonadotropin therapy for fertility preservation in cancer patients. The study found that long-acting gonadotropin-releasing hormone agonist (GnRHa) was effective in inducing oocyte maturation, reducing the risk of ovarian hyperstimulation syndrome (OHSS), and suppressing ovarian function before chemotherapy. The researchers analyzed data from ovarian stimulation cases in oncological patients and found that the use of long-acting GnRHa resulted in a higher number of cryopreserved oocytes with a maturation rate of 80%. No cases of OHSS were observed with long-acting GnRHa triggering. These findings suggest that long-acting GnRHa could be a viable option for fertility preservation in cancer patients. [Extracted from the article]

A recent report from Boston Children's Hospital provides new insights into the treatment of adolescent endometriosis. The study examined the use of gonadotropin-releasing hormone agonists (GnRHa) plus add-back therapy in adolescents with laparoscopically confirmed endometriosis. The study found that almost half of the participants continued to use GnRHa with add-back therapy beyond the recommended 12-month duration. Additionally, the study found that treatment varied widely after discontinuation of GnRHa, with many participants returning to previously trialed medical therapies. This research provides valuable information for healthcare providers and patients in managing endometriosis in adolescents. [Extracted from the article]

A recent study conducted by Shantou University College of Medicine in China explores the relationship between psychological stress and hair loss. The researchers found that stress-related corticotropin-releasing hormone (CRH) is associated with hair loss, but the mechanism by which hair follicles respond to stress and CRH is not well understood. The study used mouse models to examine the role of CRH and stress-related hair regrowth and found that chronic stress and CRH blocked hair follicle regrowth. However, the researchers also discovered that enhancing autophagy, a cellular process, may have a therapeutic effect on stress-induced hair loss. This research provides valuable insights into the understanding and potential treatment of hair loss caused by stress. [Extracted from the article]

A recent study conducted by Zhejiang University in Hangzhou, China, examined the reproductive pregnancy outcomes of patients undergoing polypectomy. The study compared the outcomes of pretreatment with long-acting gonadotropin-releasing hormone agonist (GnRH-a) plus hormone replacement therapy (HRT) with HRT-only cycles. The results showed that pretreatment with GnRH-a improved the live birth rate (LBR) for frozen-thawed embryo transfer (FET) cycles after hysteroscopic multiple polypectomies. The study also found that the number of doses of GnRH-a did not significantly impact the LBR. This research provides valuable insights into improving pregnancy outcomes for patients undergoing polypectomy. [Extracted from the article]